EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow

Jill A Ohar, Donald A Mahler, Gabrielle N Davis, David A Lombardi, Edmund J Moran iD, Glenn D Crater iD

Canadian Respiratory Journal · 22.03.2024 · 2024 · 1-8

DOI: 10.1155/2024/8034923 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Respiratory Journal, erschienen am 22.03.2024. Verfasst von Jill A Ohar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Theravance Biopharma Ireland Limited, Mylan, Theravance Biopharma US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Many patients with chronic obstructive pulmonary disease (COPD) may derive inadequate benefit from dry powder inhalers (DPIs) because of suboptimal peak inspiratory flow (sPIF).

Objectives

To assess the clinical burden of COPD by characterizing the clinical characteristics of participants with sPIF against medium-low resistance DPIs versus those with optimal PIF (oPIF) from two phase 3 clinical trials.

Methods

Baseline data were collected from two randomized, controlled, phase 3 trials (NCT03095456; NCT02518139) in participants with moderate-to-severe COPD. oPIF (60 L/min) against the medium-low resistance DPIs was used as the threshold for defining the PIF subgroups (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveAgedAged, 80 and overHumansMaleAdministration, InhalationDry Powder InhalersDyspneaSymptom BurdenFemaleAdultMiddle AgedClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Autor:innen und Institutionen

  • Section of Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA.
  • Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • Valley Regional Hospital, Claremont, NH, USA.
  • Theravance Biopharma US, Inc., South San Francisco, CA, USA.

ORCID-Profile: Edmund J Moran, Glenn D Crater

Förderung

  • Theravance Biopharma Ireland Limited
  • Mylan
  • Theravance Biopharma US

Zitieren

APA

Ohar, J. A., Mahler, D. A., Davis, G. N., Lombardi, D. A., Moran, E. J., & Crater, G. D. (2024). Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow. Canadian Respiratory Journal, 2024, 1-8. https://doi.org/10.1155/2024/8034923

Vancouver

Ohar JA, Mahler DA, Davis GN, Lombardi DA, Moran EJ, Crater GD. Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow. Canadian Respiratory Journal. 2024;2024:1-8. doi:10.1155/2024/8034923

BibTeX
@article{Ohar2024,
  author = {Ohar, Jill A and Mahler, Donald A and Davis, Gabrielle N and Lombardi, David A and Moran, Edmund J and Crater, Glenn D},
  title = {Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow},
  journal = {Canadian Respiratory Journal},
  year = {2024},
  volume = {2024},
  pages = {1--8},
  doi = {10.1155/2024/8034923}
}
Kostenlos starten →